<DOC>
	<DOCNO>NCT02956538</DOCNO>
	<brief_summary>With development application biological agent , treatment effect considerable degree improvement refractory corn 's disease . However , quite part CD patient lose response treatment use response . Moreover , due various reason , still lot limit use biological agent China , make quite part refractory CD patient lack medical treatment option . There RCT study prove thalidomide effect safety treat refractory CD lose response use biological agent Italy , object study limit child adolescent . There small sample study also confirm efficacy safety refractory corn 's disease use thalidomide , need RCT evidence .</brief_summary>
	<brief_title>Induced Adult Refractory Active Crohn 's Disease Clinical Relieving Using Thalidomide</brief_title>
	<detailed_description>It divide two group patient use randomize , double-blind . One group treat thalidomide , placebo . It unlock blind analysis effect safety thalidomide 8 week . The second , patient still use thalidomide unlock blind prove longtime treatment effect safety .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Age 1850 year old Diagnosis patient CD Disease activity : CDA â…  &gt; 150 point , endoscopic see active lesion Refractory : immunosuppressive drug biological agent use current treatment invalid and/or intolerance Fiber stenosis cause gastrointestinal obstruction symptom Fistula exclude anal fistula Pregnancy lactation Period woman fertility program study Treatment foot eight week last IFX Central peripheral nerve disease Abnormal liver renal function Heart function failure Malignant tumor Active tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>